Kinnate Biopharma Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021
Assets
Current assets:
Cash and cash equivalents
Cash at consolidated joint venture
Short-term investments
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Right-of-use lease assets
Long-term investments
Restricted cash
Deferred offering costs
Other non-current assets
Total assets
Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders' Equity
Current liabilities:
Accounts payable
Accrued expenses
Current portion of operating lease liabilities
Total current liabilities
Operating lease liabilities, long-term
Total liabilities
Redeemable convertible noncontrolling interests
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized at December 31,2023 and 2022; 0 shares outstanding at December 31, 2023 and 2022
Common stock, $0.0001 par value; 1,000,000,000 shares authorized at December 31, 2023 and 2022; 47,124,349 and 44,342,292 shares issued and outstanding at December 31, 2023 and 2022 , respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders' equity
Total liabilities, redeemable convertible noncontrolling interests and stockholders' equity

Comments